IMU's Dr Alex Hoos in GSK deal for another immune system based oncology drug, page-16

Almost a billion US for a single preclinical drug

If that doesn’t settle the market cap argument and cement our valuation at multiples of this at the very least then I don’t really know what else to say. The writing is on the wall

CF33 killed how many of the NCI-60 Solid cancer cell lines in preclinical?

Yep thats right it, every single one! Nothing else has come close, which begs the multi billion dollar question

Can big pharma risk letting CF33 really stretch it’s legs through phase 1 & 2 trails under Imugenes full ownership and control ? Or do they attempt to tame this beast now before it’s potential and worth is fully realised.